Alexza Pharmaceuticals' Adasuve approved by FDA Alexza Pharmaceuticals announced that the FDA approved Adasuve Inhalation Powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Adasuve combines Alexza's proprietary Staccato delivery system with the antipsychotic drug, loxapine.
Alexza Pharmaceuticals initiates Phase 2a study of AZ-002 in epilepsy Alexza Pharmaceuticals has initiated a Phase 2a study of AZ-002 - Staccato alprazolam -, which is being developed for the management of epilepsy in patients with acute repetitive seizures. ARS occurs in a subset of patients with epilepsy who regularly experience breakthrough seizures, despite treatment with a regular regimen of anti-epileptic drugs. Alexza expects to announce results from this study in 1H15.